Total Payments
$988.41
2024 Payments
$61.42
Companies
7
Transactions
24
Medicare Patients
5,551
Medicare Billing
$1.1M
Payment Breakdown by Category
Food & Beverage$988.41 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $988.41 | 24 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Smith+Nephew, Inc. | $269.04 | 4 | $0 (2020) |
| ABBVIE INC. | $244.53 | 7 | $0 (2024) |
| Allergan, Inc. | $243.39 | 8 | $0 (2020) |
| Kerecis Limited | $134.81 | 2 | $0 (2024) |
| Organogenesis Inc. | $57.07 | 1 | $0 (2018) |
| Integra LifeSciences Corporation | $22.51 | 1 | $0 (2024) |
| Theravance Biopharma, Inc. | $17.06 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $61.42 | 3 | ABBVIE INC. ($23.45) |
| 2023 | $53.90 | 2 | ABBVIE INC. ($53.90) |
| 2022 | $146.66 | 3 | ABBVIE INC. ($146.66) |
| 2021 | $20.52 | 1 | AbbVie Inc. ($20.52) |
| 2020 | $74.23 | 4 | Allergan, Inc. ($46.49) |
| 2019 | $316.25 | 7 | Allergan Inc. ($196.90) |
| 2018 | $196.20 | 3 | Smith & Nephew, Inc. ($122.07) |
| 2017 | $119.23 | 1 | Smith & Nephew, Inc. ($119.23) |
All Payment Transactions
24 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ | Food and Beverage | In-kind items and services | $23.45 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/13/2024 | Kerecis Limited | Kerecis Omega3 SurgiClose (Device), Kerecis Omega3 Marigen, Kerecis Omega3 Marigen | Food and Beverage | Cash or cash equivalent | $15.46 | General |
| Category: Wound Care | ||||||
| 02/06/2024 | Integra LifeSciences Corporation | TCC-EZ (Device) | Food and Beverage | In-kind items and services | $22.51 | General |
| Category: Recon-Skin and Wound | ||||||
| 10/03/2023 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/02/2023 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $30.28 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/15/2022 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $91.67 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/15/2022 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $33.33 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/10/2022 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $21.66 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/15/2021 | AbbVie Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $20.52 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/03/2020 | Allergan, Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $25.36 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/03/2020 | Allergan, Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/19/2020 | Smith+Nephew, Inc. | Santyl (Drug) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: Pharma Product | ||||||
| 10/19/2020 | Smith+Nephew, Inc. | Santyl (Drug), REGRANEX, IODOSORB | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: Pharma Product | ||||||
| 10/30/2019 | Kerecis Limited | Kerecis Omega3 Wound (Device) | Food and Beverage | Cash or cash equivalent | $119.35 | General |
| Category: Wound Care | ||||||
| 10/23/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $124.15 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/30/2019 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $12.01 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/06/2019 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $15.53 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/27/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $11.78 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/22/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/08/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/28/2018 | Organogenesis Inc. | Apligraf (Biological) | Food and Beverage | Cash or cash equivalent | $57.07 | General |
| Category: Podiatry | ||||||
| 08/09/2018 | Theravance Biopharma, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $17.06 | General |
| Category: Infectious Disease | ||||||
| 04/26/2018 | Smith & Nephew, Inc. | Santyl (Drug), Regranex, Oasis | Food and Beverage | In-kind items and services | $122.07 | General |
| Category: Pharma Product | ||||||
| 10/12/2017 | Smith & Nephew, Inc. | Regranex (Drug) | Food and Beverage | In-kind items and services | $119.23 | General |
| Category: Pharma Product | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 834 | 3,187 | $330,125 | $207,555 |
| 2022 | 7 | 1,081 | 3,658 | $342,035 | $204,055 |
| 2021 | 9 | 1,593 | 5,620 | $522,176 | $316,415 |
| 2020 | 7 | 2,043 | 7,640 | $680,774 | $407,042 |
Total Patients
5,551
Total Services
20,105
Medicare Billing
$1.1M
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 274 | 1,782 | $151,470 | $110,375 | 72.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 96 | 319 | $63,800 | $29,719 | 46.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 157 | 742 | $44,520 | $28,720 | 64.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 209 | 241 | $44,585 | $24,634 | 55.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 98 | 103 | $25,750 | $14,107 | 54.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 340 | 1,978 | $168,130 | $109,686 | 65.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 336 | 368 | $68,080 | $38,713 | 56.9% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 221 | 960 | $57,600 | $28,706 | 49.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 59 | 63 | $15,750 | $9,807 | 62.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 62 | 105 | $21,000 | $8,536 | 40.6% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Facility | 2022 | 35 | 155 | $9,300 | $6,937 | 74.6% |
| 99309 | Follow-up nursing facility visit per day, typically 25 minutes | Facility | 2022 | 28 | 29 | $2,175 | $1,672 | 76.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 501 | 3,022 | $256,621 | $171,345 | 66.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 449 | 504 | $93,240 | $53,602 | 57.5% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 374 | 1,510 | $90,360 | $45,876 | 50.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 79 | 199 | $39,800 | $16,230 | 40.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 87 | 89 | $22,250 | $14,001 | 62.9% |
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Facility | 2021 | 45 | 193 | $11,580 | $9,216 | 79.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 11 | 50 | $3,000 | $2,400 | 80.0% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Facility | 2021 | 35 | 35 | $2,625 | $2,100 | 80.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 12 | 18 | $2,700 | $1,645 | 60.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 667 | 4,159 | $352,072 | $230,130 | 65.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 638 | 700 | $129,500 | $73,300 | 56.6% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 529 | 2,277 | $136,262 | $68,405 | 50.2% |
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Facility | 2020 | 55 | 279 | $16,740 | $12,200 | 72.9% |
About Dr. Naveed Farooq, MD
Dr. Naveed Farooq, MD is a Infectious Disease healthcare provider based in Pearland, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1427165588.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Naveed Farooq, MD has received a total of $988.41 in payments from pharmaceutical and medical device companies, with $61.42 received in 2024. These payments were reported across 24 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($988.41).
As a Medicare-enrolled provider, Farooq has provided services to 5,551 Medicare beneficiaries, totaling 20,105 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Pearland, TX
- Active Since 08/24/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RI0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1427165588
Products in Payments
- AVYCAZ (Drug) $436.93
- Santyl (Drug) $149.81
- Kerecis Omega3 Wound (Device) $119.35
- Regranex (Drug) $119.23
- Apligraf (Biological) $57.07
- DALVANCE (Drug) $27.54
- TEFLARO (Drug) $23.45
- TCC-EZ (Device) $22.51
- VIBATIV (Drug) $17.06
- Kerecis Omega3 SurgiClose (Device) $15.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.